Literature DB >> 18313882

[Lactic acidosis associated with propofol during general anaesthesia for neurosurgery].

J Bordes1, E Meaudre, Y Asencio, A Montcriol, E Kaiser.   

Abstract

Propofol infusion syndrome (PRIS) is a new clinical entity reported in critically ill patients. Lactic acidosis, cardiac failure and rhabdomyolysis are the features. Lactic acidosis related to short-term propofol administration has been described during general anaesthesia. Lactic acidosis could be an early marker of PRIS. We report here a case of very early lactic acidosis in a 66-year-old-man receiving propofol during a neurosurgery. The outcome was good after discontinuation of propofol.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313882     DOI: 10.1016/j.annfar.2008.01.022

Source DB:  PubMed          Journal:  Ann Fr Anesth Reanim        ISSN: 0750-7658


  4 in total

1.  Temporary hyperlactataemia during partial hepatectomy: Report of two cases.

Authors:  Yi Zou; Jitong Liu; Yongqiong Liao; Wanmin Pei; Gaoyin Kong
Journal:  Int J Surg Case Rep       Date:  2014-12-11

2.  Clinical analysis of hyperkalemia after esophagectomy: A case report.

Authors:  Qiang Chen; Wei-Guo Zhang; Shu-Chang Chen
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

3.  Hyperlactatemia After Intracranial Tumor Surgery Does Not Affect 6-Month Survival: A Retrospective Case Series.

Authors:  Peter P de Smalen; Tom J van Ark; Robert J Stolker; Arnaud J P E Vincent; Markus Klimek
Journal:  J Neurosurg Anesthesiol       Date:  2020-01       Impact factor: 3.969

4.  Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study.

Authors:  Russel J Roberts; Jeffrey F Barletta; Jeffrey J Fong; Greg Schumaker; Philip J Kuper; Stella Papadopoulos; Dinesh Yogaratnam; Elise Kendall; Renee Xamplas; Anthony T Gerlach; Paul M Szumita; Kevin E Anger; Paul A Arpino; Stacey A Voils; Philip Grgurich; Robin Ruthazer; John W Devlin
Journal:  Crit Care       Date:  2009-10-29       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.